Early promising results in malaria vaccine trial in Mali

Jan 23, 2008

A small clinical trial conducted by an international team of researchers in Mali has found that a candidate malaria vaccine was safe and elicited strong immune responses in the 40 Malian adults who received it.

The trial was the first to test this vaccine candidate, which is designed to block the malaria parasite from entering human blood cells, in a malaria-endemic country. Based on these promising results, the research team is now conducting trials of this vaccine in 400 Malian children aged 1 to 6 years. Malaria is a leading killer in Africa and other developing countries, claiming more than 1 million lives each year, most of them children.

Lead investigator Mahamadou A. Thera M.D., MPH, and 16 other co-authors of the newly published study are based at the Malaria Research and Training Center at the University of Bamako, Mali. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, supported the trial and helps fund the Center. University of Maryland School of Medicine researcher Christopher Plowe, M.D., MPH, was the co-leader of the study.

The trial enrolled volunteers living in Bandiagara, a rural town in northeast Mali with a heavy burden of malaria. In this relatively dry region, almost no new infections occur during the driest month of the year, March, but people typically get up to 60 malaria-transmitting mosquito bites per month in August and September, when the rainy season peaks.

A total of 60 participants were assigned at random to receive either a full or half-dose of the candidate malaria vaccine or a licensed rabies vaccine, which served as a control. Each volunteer received three injections, spaced one month apart. Injections began in late December 2004, at the end of the malaria transmission season. As expected, all volunteers had significant levels of antibodies against malaria parasites detectable in their blood at the beginning of the trial, signaling that they had prior exposure to malaria parasites.

Those who received the candidate vaccine tolerated it very well and experienced a significant boost (up to a sixfold rise) in levels of vaccine-specific antibodies, while those who received the rabies vaccine had declining levels of antibodies as the rainy season receded.

Source: NIH/National Institute of Allergy and Infectious Diseases

Explore further: Anti-cholinergic drugs impair physical function in elderly patients

add to favorites email to friend print save as pdf

Related Stories

Huge waves measured for first time in Arctic Ocean

31 minutes ago

As the climate warms and sea ice retreats, the North is changing. An ice-covered expanse now has a season of increasingly open water which is predicted to extend across the whole Arctic Ocean before the middle ...

Underwater elephants

32 minutes ago

In the high-tech world of science, researchers sometimes need to get back to basics. UC Santa Barbara's Douglas McCauley did just that to study the impacts of the bumphead parrotfish (Bolbometopon muricatum) on cor ...

Mysterious molecules in space

36 minutes ago

Over the vast, empty reaches of interstellar space, countless small molecules tumble quietly though the cold vacuum. Forged in the fusion furnaces of ancient stars and ejected into space when those stars ...

Recommended for you

FDA to start regulating lab-developed tests

Jul 31, 2014

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Sepp
not rated yet Jan 23, 2008
Question is: did they contract malaria or not? Citing only the "vaccine specific antibodies" it is really impossible to see whether the vaccine was effective. The real data we'd need to say it is a worthwhile intervention is differences in actual cases of malaria. Should that not be part of the article?